普乐沙福在自体移植外周血干细胞动员中应用策略的研究进展  

Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation——Review

作　　者：方颖 叶佩佩[2] FANG Ying;YE Pei-Pei(Health Science Center,Ningbo University,Ningbo 315000,Zhejiang Province,China;Department of Hematology,The Affiliated People′s Hospital of Ningbo University,Ningbo 315000,Zhejiang Province,China)

机构地区：[1]宁波大学医学部,浙江宁波315000 [2]宁波大学附属人民医院血液内科,浙江宁波315000

出　　处：《中国实验血液学杂志》2024年第1期322-326,共5页Journal of Experimental Hematology

基　　金：浙江省医药卫生科技计划项目(2022KY1184);宁波市医学重点学科建设项目(2022-S05)。

摘　　要：普乐沙福(plerixafor)是一种小分子趋化因子受体4(CXCR4)类似物,通过阻断基质细胞衍生因子-1(SDF-1)和CXCR4的相互作用,将造血干细胞从骨髓释放入外周血,用于外周血干细胞(PBSC)动员。由于plerixafor在国内获批上市时间较短且价格昂贵,临床应用经验较少。临床研究人员正积极探索plerixafor的最佳使用策略,提高动员采集成功率并且降低成本。本文对近几年来plerixafor应用策略的最新研究进展作一综述,总结plerixafor在自体造血干细胞移植(auto-HSCT)中的最佳应用策略。Objective:Plerixafor,an analog of C-X-C motif chemokine receptor 4(CXCR4),which allows the release of stem cells from the bone marrow into peripheral blood(PB)by disrupting the interaction of CXCR4 with stromal cellderived factor-1(SDF-1),is effective in mobilization for peripheral blood stem cells(PBSC).Due to its market approval has not been long and its high price in China,the clinical application of plerixafor is still very limited.The clinicians are actively seeking the optimal use of plerixafor to improve the success rate of PBSC collection and reduce the cost.This article reviews the latest research progress related to plerixafor application,in order to summarize the optimal use of plerixafor in autologous hematopoietic stem cell transplantation(auto-HSCT).

关 键 词：普乐沙福 动员 淋巴瘤 多发性骨髓瘤 自体造血干细胞移植 

分 类 号：R457.7[医药卫生—治疗学]